Inclusion Criteria:  Patient is ≥ 20 years old. Written informed consent can be obtained. The enrolled coronary vessel only has one target coronary lesion required stenting. The target coronary lesion is 50 to 100% stenosis and stenting is required. Coronary artery de novo lesion requiring implantation of a single drug eluting stent with length ≥ 32 mm. Patients are able to tolerate dual antiplatelets for at least six months.  Exclusion Criteria:  Patient is unwilling to join this study. Patients have end-stage renal disease under dialysis, chronic kidney disease (serum creatine > 1.5 mg/dL), symptomatic heart failure, active cancer, high bleeding risk, ST elevation myocardial infarction or hemodynamic unstable non-ST elevation myocardial infarction. Coronary lesion with following features: heavily calcification, ostial lesion, lesions requiring post-stenting side branch dilatation and lesions required more than one stent to treat. The left ventricular ejection fraction is ≤ 40%. No scheduled operation within six months after the coronary stenting is allowed unless continuous dual antiplatelet use is acceptable. Patients are unsuitable or unable to receive CCTA. Pregnant women or women with breast feeding or suitable pregnant women without contraception during the study period. Patient is currently participating another interventional trial.